HBPCF (Helix BioPharma) Loans Receivable: $0.00 Mil (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Loans Receivable?

Helix BioPharma HBPCF 28 Loans Receivable is $0.00 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's Loans Receivable for the quarter that ended in Apr. 2026 was $0.00 Mil.

Helix BioPharma Loans Receivable Related Terms

Helix BioPharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Loans Receivable Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Helix BioPharma (HBPCF) has a Loans Receivable of $0.00 Mil as of Apr. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Loans Receivable too high?
Helix BioPharma's current Loans Receivable is $0.00 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Loans Receivable compare to VRTX and REGN?
Helix BioPharma's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Loans Receivable is $0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price